MGTA Stock Price History and Quote Analysis: Insights for Investors
Magenta Therapeutics, Inc.
Stock Price Today
Magenta Therapeutics, Inc. (MGTA) stock declined over -7.74%, trading at $0.70 on NASDAQ, down from the previous close of $0.76. The stock opened at $0.71, fluctuating between $0.69 and $0.76 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company Information
| Employees | 67 |
| Beta | 2.114107 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Magenta Therapeutics, Inc. (NASDAQ: MGTA) stock price is $0.70 in the last trading session. During the trading session, MGTA stock reached the peak price of $0.76 while $0.69 was the lowest point it dropped to. The percentage change in MGTA stock occurred in the recent session was -7.74% while the dollar amount for the price change in MGTA stock was -$0.06.
The NASDAQ listed MGTA is part of Biotechnology industry that operates in the broader Healthcare sector. Magenta Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Jason Gardner DPHIL, Ph.D.
Co-Founder, Chief Executive Officer, Pres & Director
Dr. Lisa M. Olson Ph.D.
Head of Research & Chief Scientific Officer
Mr. Jim Haney
Senior Director of Investor Relations
Lyndsey Scull
Director of Corporation Communications
Ms. Kristen Stants
Chief People Officer
Ms. Caren Deardorf
Chief Commercial Officer
Mr. David Wayne Nichols
Chief Technical Officer
Mr. Thomas W. Beetham J.D., MBA
Chief Legal Officer & Sec.
Ms. Catherine Monaghan
Head of Clinical Devel. Operations
Shan Wu
Head of Investor Relations
Mr. Stephen F. Mahoney J.D., MBA
Pres, Chief Financial & Operating Officer and Treasurer
MGTA's closing price is 117.94% higher than its 52-week low of $0.32 where as its distance from 52-week high of $1.81 is -61.35%.
Number of MGTA employees currently stands at 67.
Official Website of MGTA is: https://www.magentatx.com
MGTA could be contacted at phone 857 242 0170 and can also be accessed through its website. MGTA operates from 100 Technology Square, Cambridge, MA 02139, United States.
MGTA stock volume for the day was 375.91K shares. The average number of MGTA shares traded daily for last 3 months was 247.98K.
The market value of MGTA currently stands at $42.44M with its latest stock price at $0.70 and 60.66M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com